The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2026 | Relapse patterns and sequencing of CD19 CAR T-cell therapies in MCL: lessons from DLBCL and beyond
Elise Chong, MD, Abramson Cancer Center at the University of Pennsylvania, discusses how the use of CD19-directed CAR T-cell therapies differs between diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL). Dr Chong highlights the need for different long-term treatment expectations in DLBCL and MCL and emphasizes the importance of prior treatment history when determining therapy sequencing. This interview took place at the 14th Annual Meeting of the Society of Hematologic Oncology (SOHO 2026) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yeah, so I think CAR T-cells for diffuse large B-cell and CAR T-cells for mantle cell lymphoma, even though we’re targeting the same antigen CD19, are very different. When we look at the relapses in diffuse large B-cell lymphoma, we see that most of those relapses happen within the first six months. And really, after one to two years, those relapses are significantly lower. And it’s actually fairly rare...
Yeah, so I think CAR T-cells for diffuse large B-cell and CAR T-cells for mantle cell lymphoma, even though we’re targeting the same antigen CD19, are very different. When we look at the relapses in diffuse large B-cell lymphoma, we see that most of those relapses happen within the first six months. And really, after one to two years, those relapses are significantly lower. And it’s actually fairly rare. Versus mantle cell, actually, with the longer-term data from the brexu-cel data, we see that those relapses are continuing out over time. And we don’t see that plateau that we see in diffuse large B-cell lymphoma. So I do think it’s a different approach in terms of long-term expectations. There’s also a question about sequencing and how does that really impact the management. And I think the other piece for mantle cell lymphoma that we’ve learned for CAR T-cells is really that we know that bendamustine-based regimens, either bendamustine with rituximab or bendamustine-rituximab with BTK inhibitors afterwards, the bendamustine can really impact the outcomes to CAR T-cells. And so because that’s a frequently utilized therapy in mantle cell lymphoma, it’s just something to be cognizant of for patients who are receiving CAR T-cells after that.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
